Starting with the development of a unique cell-based system for the identification of compounds modulating cardiac rhythm, Fluofarma developed key capacities to support drug discovery in the field of cardiovascular diseases.
NEW ! Endothelial cell activation | HUVECs | PF 1.6 |
NEW! Calcium assay | iPSC-derived cardiomyocytes: iCell2® |
PF 1.7 ⤵ TEST SHEET |
NEW ! MEA assay | iPSC-derived cardiomyocytes: Cor 4U® – iCell2® |
CV 5.14 |
hERG channel | HEK 293 | CV 5.6 |
hERG trafficking | HEK 293 | CV 5.10 |
hNav1.5 channel | HEK 293 | CV 5.7 |
hKir2.1 channel | HEK 293 | CV 5.8 |
hKir2.1 trafficking | HEK 293 | CV 5.13 |
hCav1.2 channel | HEK 293 | CV 5.9 |
Inositol triphosphate receptor channel function |
H9C2 Cells | PF 3.21 |
EX VIVO | ||
Spontaneously beating right atrium | Guinea-pig – Rabbit | CV 5.1 |
Stimulated left atrium | Guinea-pig – Rabbit | CV 5.11 |
Purkinje fiber | Rabbit – Dog | CV 5.5 |
Papillary muscle | Guinea-pig | CV 5.12 |
> human induced Pluripotent Stem Cell derived Cardiomyocytes (iPSC-CMs) are functionally synced, spontaneously generating heart-beating cycles
> High-throughput monitoring of calcium bursts by FLIPR® Tetra, to identify compounds modulating cardiac rhythm
> A cell-based system suited for screening, drug profiling and cardiotoxicity studies